Watson/Genelabs Prestara "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genelabs will conduct six-month clinical trial to confirm a positive effect for Prestara (prasterone, formerly Aslera) with bone mineral density as the primary endpoint, following an Aug. 28 "approvable" letter. Genelabs' study GL95-02 showed an effect on bone mineral density in 381 women with mild to moderate systemic lupus erythematosus; the other pivotal trial used steroid reduction as the endpoint. FDA's Arthritis Advisory Committee had expressed concern about prasterone's failure to reach prospectively defined primary endpoints at its April 19, 2001 meeting, and FDA issued a "not approvable" letter June 26, 2001. Additional analyses from GL95-02 were submitted in February 2002, showing significant increases in lumbar spine and hip bone mineral densit
You may also be interested in...
Genelabs Prestara U.S. Confirmatory Trial On Schedule Despite EU Setback
Genelabs’ decision to withdraw its European Marketing Authorization Application for the lupus therapy prasterone will not affect pursuit of FDA approval, the company maintained June 7.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.